Bioo Scientific is presenting a seminar describing the in-vivo targeted transport of RNAi mediators using antibody conjugate technology, at the 2009 Pfizer RNAi Forum in Groton, CT.
Bioo's technology uses antibody- and peptide-based agents for directed delivery into cultured cells and animal-disease models.
Dr Lance Ford, Bioo's vice president of research and business development, said: 'using engineered antibodies against various cell surface receptors, RNAi mediators are loaded in bulk onto antibody complexes, followed by an intravenous administration of the targeted RNAi mediators.
'These molecules are taken up by specific cells via receptor-mediated endocytosis and dissociated in endosomes leading to the release of the RNAi mediators.'
